BridgeBio Pharma, Inc. — Director's Dealing 2025

Jul 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-07-01

Reporting Person: Kumar Neil (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-01	Common Stock	S	18300	$42.5015	Disposed	4780147	Indirect
2025-07-01	Common Stock	S	1700	$42.8841	Disposed	4778447	Indirect
2025-07-02	Common Stock	S	20000	$42.7268	Disposed	4758447	Indirect
2025-07-01	Common Stock	S	18400	$42.505	Disposed	977286	Indirect
2025-07-01	Common Stock	S	1600	$42.8925	Disposed	975686	Indirect
2025-07-02	Common Stock	S	20000	$42.7257	Disposed	955686	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	217404	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

F2: Represents the weighted average sale price of the shares sold from $41.80 to $42.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

F4: Represents the weighted average sale price of the shares sold from $42.81 to $42.96 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F5: Represents the weighted average sale price of the shares sold from $42.145 to $43.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F6: Represents the weighted average sale price of the shares sold from $41.81 to $42.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F7: Represents the weighted average sale price of the shares sold from $42.81 to $42.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F8: Represents the weighted average sale price of the shares sold from $42.22 to $43.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.